

8 February 2011

**Colonel D. Gray Heppner, Jr., M.D., F.A.C.P., F.R.G.S.**  
**Walter Reed Army Institute of Research**  
**Silver Spring, Maryland USA**  
**donald.heppner@us.army.mil**

Colonel Heppner holds a B.A. in German and Chemistry ('78) and an M.D. ('83) from the University of Virginia, and completed residency and fellowship training at the Universities of Minnesota and Maryland. He is board certified in internal medicine and infectious diseases, and is an elected fellow of the American College of Physicians and of the Royal Geographical Society (London).

Most recently, COL Heppner was Deputy Director ('08-'11) of the Walter Reed Army Institute of Research (WRAIR, pronounced "rare"), the Department of Defense's Center of Excellence for Infectious Diseases and Military Psychiatry. At WRAIR and its Overseas Research Units in Asia, Africa and Europe, 2000 military and civilian scientists work to develop United States Food and Drug Administration (FDA)-approved diagnostic devices, drugs and vaccines to safeguard both Soldier and Public Health.

The WRAIR played a crucial role in the development and licensure of FDA-approved antimalarial drugs (doxycycline, mefloquine, Malarone, etc.), vaccines against hepatitis A, Japanese encephalitis, meningococcal meningitis, adenovirus 4&7, and anthrax, and a rapid diagnostic test for malaria. At WRAIR, current infectious disease work efforts include development of vaccines for HIV, dengue, and shigellosis. Specific malaria efforts include licensure of life-saving drug for the treatment of severe malaria (intravenous artesunate) and co-development of the malaria vaccine "RTS,S" for both pediatric and adult indications.

Previously Colonel Heppner was Director, Division of Malaria Vaccine Development ('99-'08) at WRAIR leading malaria vaccine development in the USA and Europe, and clinical and field trials in the USA, Thailand, Mali, and Kenya. Of note, he was Assistant Chief, then Chief of Medicine & Immunology ('93-'97) at the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand where he conducted preclinical, clinical and field trials of malaria vaccines and drugs. COL Heppner has published on the U.S Army's efforts in leading medical journals. He is a Member of Order of Military Medical Merit, a Finalist, Berry Prize for U.S. Medicine ('08), and recipient of the Kiwanis International Foundation's World Service Medal for his efforts in vaccine development.

Colonel Heppner, a recognized authority on global health, is an elected member of the Council of Foreign Relations, New York ('10), an independent, nonpartisan membership organization, think tank, and publisher dedicated to addressing foreign policy choices facing the United States, which provides an important policy forum to addresses the critical relevance and interplay of disease, public health and economics.

## **COL Heppner Bibliography from 2005 by Research and Development Category**

### **Phase 2 Trials in Endemic Lands**

Thera MA, Doumbo OK, Coulibay D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Harrison ST, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, **Heppner DG Jr**, Plowe CV. Strain-specific efficacy of a blood stage malaria vaccine. Submitted to N Eng J Med.

Woodring JV, Ongut B, Schnabel D, Waitumbi JN, Olsen CH, Winnatealsh DS, **Heppner DG Jr**, Polhemus ME. Evaluation of recurrent parasitemia after artemether-lumefantrine treatment for uncomplicated malaria in children in western Kenya. Am J Trop Med Hyg 2010;83(3):458-64.

Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR, **Heppner DG Jr**. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental *Plasmodium falciparum* infection. Vaccine 2010;28(31):5135-44.

Waitumbi JN, Anyona SB, Hunja CW, Kifude CM, Polhemus ME, Walsh DS, Ockenhouse CF, **Heppner DG**, Leach A, Lievens M, Ballou WR, Cohen JD, Sutherland CJ. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of *P. falciparum* in adults participating in a malaria vaccine clinical trial. PLoS One 2009; 17;4(11):e7849.

Polhemus ME, Remich SA, Ongut BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, Kester KE, Ockenhouse CF, Stewart A, Krzych U, Ofori-Anyinam O, Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Moris P, Leach A, Cohen J, Ballou WR, **Heppner DG Jr**. Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area. PLoS One. 2009;4(7):e6465.

Ongut BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, **Heppner DG**, Withers MR, and the MSP1 Malaria Vaccine Working Group. Blood stage vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS Clinical Trials 2009;4(3):e4708.

Polhemus MA, Remich S, Ongut B, Lievens M, Leach A, Ballou WR, **Heppner DG**. Cure of malaria with atovaquone-proquanil in malaria immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis. Antimicrob Agents Chemother 2008;52(4):1493-5.

**Heppner DG Jr**, Walsh DS, Uthaimongkol N, Tang DB, Tulyayon S, Permpanich B, Wimonwatrawatee T, Chuanak N, Laoboonchai A, Sookto P, Brewer TG, McDaniel P, Eamsila C, Yongvanitchit K, Uhi K, Kyle DE, Keep LW, Miller RE, Wongsrichanalai C. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of *Plasmodium falciparum* and *P. vivax* malaria in western Thailand. Am J Trop Med 2005;73(5):842-49.

## Phase 1 Trials in Endemic Lands

Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, **Heppner DG**, Plowe CV. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS One 2010;5(2):e9041.

Lyke KE, Daou M, Diarra I, Kone A, Kouriba B, Thera MA, Dutta S, Lanar D, **Heppner DG Jr**, Doumbo OK, Plowe CV, Sztein MB. Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: Results of a Phase I randomized trial. Vaccine 2009;27(15):2171-6.

Thera MA, Doumbo KO, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Sagara I, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, **Heppner DG**, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusa A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE 2008;23;3(1):e1465.

Macete E, Aponte JJ, Guinovart C, Sacarlal J, Ofori-Anyinam O, Manomando I, Espasa M, Bevilacqua B, Leach A, Dubois M-C, **Heppner DG**, Tello L, Milman J, Cohen J, Dubovsky F, Tornieporth N, Thompson R, Alonso P. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 years in Mozambique. Trop Med Int Health 2007;12(1):37-46.

Stoute J, Gombe J, Withers MR, Siangala J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs CL, Wites J, **Heppner DG Jr** and the MSP-1 Malaria Vaccine Working Group. Phase 1 randomized double-blind safety and immunogenicity trial of *Plasmodium falciparum* malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in Western Kenya. Vaccine 2007;25(1):176-84.

Withers MR, McKinney D, Ongutu BR, Waitumbi JN, Milman JB, Apollo OJ, Allen OG, Tucker K, Soisson LA, Diggs C, Leach A, Wites J, Dubovsky F, Stewart VA, Remich SA, Cohen J, Ballou R, Holland CA, Lyon JA, Angov E, Stoute JA, Martin SK, **Heppner DG Jr**, and the MSP-1 Malaria Vaccine Working Group. Phase Ib, Dose-Escalation Trial of an MSP-1 Malaria Vaccine Candidate in Kenyan Children. PLoS Clin Trials 2006;1(7):e32.

Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, **Heppner DG Jr**, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV and the Mali FMP1 Working Group. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults; results of a phase 1 randomized trial. PLoS Clin Trials 2006;1(7):e34.

Stoute JA, **Heppner DG Jr**, Mason C, Siangala J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of Western Kenya. Am J Trop Med Hyg 2006;75(1):166-70.

## **Phase 1 Trials in Endemic Lands (continued)**

Bojang KA, Olodude F, Pinder M , Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, Kester KE, **Heppner DG**, Cohen JD, Tornieporth T, Milligan PJ. Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. *Vaccine* 2005;23(32):4148-57.

## **Phase 2 Trials in Naïve Populations**

Vahey MT, Wang Z, Kester KE, Cummings J, **Heppner DG Jr**, Nau ME, Ofori-Anyinam O, Cohen J, Coche T, Ballou WR, Ockenhouse CF. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. *J Infect Dis* 2010;201(4):580-9.

Kester KE, Cummings JF, Ofori-Anyinam O, Krzych U, Moris P, Ockenhouse CF , Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, **Heppner DG** and the RTS,S Evaluation Group. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naïve adults; safety, efficacy and immunologic associates of protection. *J Infect Dis* 2009;200(3):337-46

Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MK, Nielsen R, Krzych U, Tierney E, Ware L, Dowler M, Hermsen CC, Suaerwein RW, de Vias SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, **Heppner DG Jr**. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) in adjuvant system AS01B or AS02A. *PLoS One* 2009;4(4):e5254.

Kester KE, Cummings JF, Ockenhouse CF, Nielsen R, Hall BT, Gordon DM, Schwenk RJ, Krzych U, Holland CA, Richmond CA, Dowler MG, Williams J, Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie MA, Ballou WR, Cohen J, **Heppner DG Jr** and the RTS,S Malaria Vaccine Working Group. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. *Vaccine* 2008;26(18):2191-202.

Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, **Heppner DG**, Hall T, Wellde BT, White K, Sun P Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wites J, Wirtz R, Cohen J, Ballou W and the RTS,S Malaria Vaccine Evaluation Group. A phase I/IIa safety, immunogenicity, and efficacy bridging study of a two-dose regimen of liquid and lyophilized formulations of the recombinant candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. *Vaccine* 2007;25(29):5359-66.

Ockenhouse CF, Hu WC, Kester KE, Cummings JF, Stewart A, **Heppner DG**, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, Burke DS. Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. *Infect Immun* 2006;74(10):5561-73.

## **Phase 2 Trials in Naïve Populations (continued)**

Dunachie SJ, Walther M, Vuola JM, Webster D, Keating SM, Berthoud T, Andrews L, Bejon P, Poulton I, Butcher G, Watkins K, Sinden RE, Leach A, Moris P, Tornieporth N, Schneider J, Dubovsky F, Tierney E, Williams J, **Heppner DG Jr**, Gilbert SC, Cohen J, Hill AV. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. *Vaccine* 2006;24(15):2850-9.

## **Phase 1 Trials in Naïve Populations**

Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, **Heppner DG**; MSP-1 Working Group. Phase I safety and immunogenicity trial of FMP1/AS02A, a *Plasmodium falciparum* MSP-1 asexual blood stage vaccine. *Vaccine* 2006;24(15):3009-17.

Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Ofori-Anyinam O, De-Kock E, Ballou WR, **Heppner DG Jr**. Phase I dose escalation safety and immunogenicity trial of *Plasmodium falciparum* apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. *Vaccine* 2007;25(21):4203-12.

## **Preclinical Trials in Monkeys**

Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, Limsalakpatch A, Stewart VA, Lanar DE, Dutta S, Angov E, Ware LA, Bergmann-Leitner ES, House B, Voss G, Dubois MC, Cohen JD, Fukuda MM, **Heppner DG**, Miller RS. Evaluation of the safety and immunogenicity of *Plasmodium falciparum* apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. *Vaccine* 2009;28(2):452-62.

Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, Soisson L, Diggs CL, **Heppner DG**, Lanar DE, Collins WE, Barnwell JW. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. *PLoS One*. 2009;4(12):e8138.

Mettens P, Dubois PM, Demoitié MA, Bayat B, Donner MN, Bourguignon P, Stewart VA, **Heppner DG Jr**, Garçon N, Cohen J. Improved T cell responses to *Plasmodium falciparum* circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. *Vaccine* 2008;26(8):1072-82.

Stewart VA, McGrath S, Krieg AM, Larson NS, Angov E, Smith CL, Brewer TG, **Heppner DG Jr**. Activation of innate immunity in healthy *Macaca mulatta* macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. *Clin Vaccine Immunol* 2008;15(2):221-6.

Pichyangkul S, Kum-Arb U, Youngvanitchit K, Limsalakpatch A, Gettayacamin M, Lanar DE, Ware LA, Stewart VA, **Heppner DG**, Mettens DG, Cohen JD, Ballou WR, Fukuda M. Pre-clinical evaluation of safety and immunogenicity of *Plasmodium falciparum* LSA1/AS01B when administered separately or concurrently with RTS,S/AS01B in rhesus primates. *Infect Immun* 2008;76(1):229-36.

## Preclinical Trials in Monkeys (continued)

Stewart VA, McGrath SM, Pau MG, Mettens P, Dubois PM, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie M-A, Weverling GJ, Bayat B, Custers JHHV, Dubois M-C, Cohen J, Goudsmit J, **Heppner DG Jr.** Priming with an Adenovirus 35–circumsporozoite (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to *Plasmodium falciparum* CS to that with either vaccine alone. *Infect Immun* 2007;75(5):2283-90.

Walsh DS, Gettayacamin M, Leitner WW, Stewart VA, Marit G, Pichyangkul S, Gosi P, Tongtawe P, Kester KE, Holland CA, Kolodny K, Cohen J, Voss G, Ballou WR, **Heppner DG.** Heterologous prime-boost immunization in rhesus macaques by particle-mediated epidermal delivery of *Plasmodium falciparum* circumsporozoite protein-encoding DNA followed by intramuscular RTS,S+AS02A. *Vaccine* 2006;24(19):4167-78.

Stewart AV, Walsh DS, McGrath S, Davis S, Hess A, Ware LA, Kester KE, Cummings JF, Voss G, Delchambre M, Cohen JD, **Heppner DG.** Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. *Vaccine* 2006;24(42-43):6493-502.

Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, Kester KE, Cummings JF, Burge JR, Voss G, Delchambre M, Garcon N, Tang DB, Cohen JD, **Heppner DG Jr.** Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. *Vaccine*. 2006 Oct 30;24(42-43):6483-92.

## Antigen Production/Characterization

VanBuskirk KM, O'Neill MT, De La Vega P, Maier AG, Krzych U, Williams J, Dowler MG, Sacci JB Jr, Kangwanrangsang N, Tsuboi T, Kneteman NM, **Heppner DG Jr.**, Murdock BA, Mikolajczak SA, Aly AS, Cowman AF, Kappe SH. Preerythrocytic, live-attenuated *Plasmodium falciparum* vaccine candidates by design. *Proc Natl Acad Sci U S A*. 2009;106(31):13004-9.

Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, **Heppner DG**, Lanar DE. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for *Plasmodium falciparum*. *Infect Immun* 2005;73(4):2109-15.

## Basic Science

Shott J, McGrath S, Pau MG, Custers J, Ophorst O, Demoitie MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, **Heppner DG**, Stewart VA. Immunogenicity of recombinant human adenovirus 5 and 35-vectored *P. falciparum* circumsporozoite surface protein vaccines in mice. *Vaccine* 2008;26(23):2818-23.

Brando C, Ware LA, Freyberger H, Kathcart A, Barbosa A, Cayphas S, Demoitie MA, Mettens P, **Heppner DG**, Lanar DE. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. *Infect Immun* 2007;75(2):838-45.

Kifude CM, Polhemus ME, **Heppner DG**, Withers MR, Ongutu BR, Waitumbi JN. Hemoglobin Kenya among Luo adults and young children in malaria holoendemic Western Kenya: screening by HPLC and confirmation by PCR. *Hemoglobin* 2007;31(4):401-8.

## **Basic Science (continued)**

Waitumbi JN, Kifude CM, Withers MR, **Heppner DG**, Ongutu BR. Hb G-Philadelphia or Stanleyville II? When the phenotype and genotype do not agree. European J Haematol 2007;79(2):177-8.

Yoon I-K, Angov E, Larson D, **Heppner DG**, Cummings JF, Stewart A. Characterization of a human reference standard for *Plasmodium falciparum* merozoite surface protein-1(42) antibody. Am J Trop Med Hyg 2005;72(6):714-8.

## **Reviews/Book Chapters/Letters**

**Heppner DG**, Moran KA, Kester KE, Cummings, JF. *Prospects for a travelers' malaria vaccine*, in Travelers' Malaria, Patricia Schlagenhauf editor, Marcell Dekker Inc. publisher, 2007.

**Heppner DG**, Schwenk RJ, Arnot D, Sauerwein RW, Luty AJF. The dog that did not bark: malaria vaccines without antibodies. Trends Parasitol 2007;23(7):293-6.

**Heppner DG Jr.** Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ongutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Witten J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: Progress at the Walter Reed Army Institute of Research. Vaccine 2005;23(17-18):2243-50.

## **End**

"There must be a beginning of any great matter, but the continuing unto the end until it thoroughly be finished yields the true glory."

Sir Francis Drake, 1587